(Q54616415)

1 June 2018

title

The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. (English)

1 reference

1 June 2018

0 references

5

Jahn M Nesland

1 reference

1 June 2018

author name string

Qinghua Wu

1

1 reference

1 June 2018

Zhenhe Suo

2

1 reference

1 June 2018

Gunnar B Kristensen

3

1 reference

1 June 2018

Mark Baekelandt

4

1 reference

1 June 2018

language of work or name

English

0 references

publication date

23 February 2006

1 reference

1 June 2018

published in

Gynecologic Oncology

1 reference

1 June 2018

volume

102

1 reference

1 June 2018

issue

1

1 reference

1 June 2018

page(s)

15-21

1 reference

1 June 2018

The protein tyrosine kinase family of the human genome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

RTK mutations and human syndromeswhen good receptors turn bad.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

eph, the largest known family of putative growth factor receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Ephrin signaling in vivo: look both ways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Expression and functional effects of Eph receptor tyrosine kinase A family members on Langerhans like dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Inhibition of tumor growth and angiogenesis by soluble EphB4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Ephrin B1 is expressed on human luteinizing granulosa cells in corpora lutea of the early luteal phase: the possible involvement of the B class Eph-ephrin system during corpus luteum formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

FHIT (fragile histidine triad) gene analysis in cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Coexpression of ephrin-Bs and their receptors in colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Prognostic significance ofEPHB6, EFNB2, andEFNB3 expressions in neuroblastoma

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

inferred from DOI database lookup

7 January 2021

based on heuristic

Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Expression of Ephb2 and Ephb4 in breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Eph receptors and ephrin ligands: embryogenesis to tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Radiation sensitization by inhibition of activated Ras.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

The influence of Ras pathway signaling on tumor radiosensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Ras inhibition amplifies cisplatin sensitivity of human glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

EphB receptor activity suppresses colorectal cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.034

10.1016/J.YGYNO.2005.11.034

7 January 2021

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018